This trial is evaluating whether Startle Adjuvant Rehabilitation Therapy (START) will improve 6 primary outcomes in patients with Stroke. Measurement will happen over the course of end of training.
This trial requires 54 total participants across 2 different treatment groups
This trial involves 2 different treatments. Startle Adjuvant Rehabilitation Therapy (START) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase < 1 and are in the first stage of evaluation with people.
Stroke is a complex problem, and its presentation is varied. Symptoms of stroke include changes in sensations such as numbness, weakness in the arms or legs, or loss of sensation or taste. These sensations may become worse over time. Weakness is present in one or both arms or legs. Tossing the arms or legs may produce weakness. People with symptoms such as these do not need immediate medical attention. The use of a neurology examination may help confirm a diagnosis.
Stroke is a neurological disorder that causes disruptions in the brain and impair functional abilities. For about two thirds of a million stroke cases, the exact cause of the disorder is unknown. The main risk factors for stroke are high blood pressure, smoking and Diabetes mellitus. This article gives a brief overview of the main symptoms and risk factors.
A variety of treatments are available to manage or improve a patient's condition after a stroke. These may be targeted to the individual's needs. The National Institute for Health Stroke Scale may be valuable for selecting treatment for individuals after a stroke. The scale allows stroke clinicians to compare the efficiency of different treatment choices for the stroke patient.
If the time from onset to surgery is short, there are good chances that an acute thrombotic stroke can be cured with reasonable chances of good functional outcome; however, if the time from onset to surgery is long, a large and potentially life-threatening hemorrhagic stroke is unlikely to be cured.
Approximately 25,000 people in the United States will have a stroke each year. This contributes to 15% of all strokes seen by family physicians in the United States. Stroke in children is the most common manifestation in the first decade of life.
Stroke is common. Risk factors and stroke can be predicted and modified. Stroke patients can be effectively treated using existing therapies. Stroke care is an evolving profession.
A new drug, efalizumab is now in human clinical trials, with promising preliminary evidence, to help in the short term recovery of walking in adult stroke patients. Eralizumab reduces swelling, relieving pressure on the brain for 6 days prior to and after the stroke event. It is now being evaluated in clinical trials, either alone, in combination with corticosteroids or with anti-inflammatory agents. Trials could take many years to complete and the effects of efalizumab may be subtle because the dose has to be carefully controlled to minimize side effects such as nausea and bronchospasm.
Despite anecdotal reports of people responding to startle treatment, our research demonstrates that the effectiveness of treatment is not supported by this finding. It will be imperative to determine if the treatment can lead to any measurable change in the participants' outcomes.
The rehabilitation therapy performed for 4 weeks by a clinician after a brain insult was less effective for patients with non-hemispatialized stroke than that for patients with hemispheric strokes. The noninvasive rehabilitation therapy performed by clinicians might be a more effective method. This treatment may be considered an effective adjuvant rehabilitation therapy.
About 50 years of age is the average age when a person with acute stroke suffers his or her first stroke. As our population ages, the incidence of stroke will increase. Therefore, preventive campaigns must be given more attention for those people who are about to have this common risk factor\n
Startle adjuvant rehabilitation therapy is probably not as effective as claimed but may improve or change behaviour and thus reduce risk of subsequent falls in older adults.
This review concludes that there is a large and growing number of randomized, controlled trials assessing thrombolytic interventions, and that an improved standard of care is probably achievable.